Tripathi BK, Qian X, Mertins P, et al. CDK5 is a major regulator of the tumor suppressor DLC1. J Cell Biol. 2014;207(5):627-42. doi:10.1083/jcb.201405105
Yoda A, Adelmant G, Tamburini J, et al. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015;21(1):71-5. doi:10.1038/nm.3751
Konermann S, Brigham MD, Trevino AE, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517(7536):583-8. doi:10.1038/nature14136
Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111(51):E5564-73. doi:10.1073/pnas.1419260111
Liu Y, Asnani A, Zou L, et al. Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med. 2014;6(266):266ra170. doi:10.1126/scitranslmed.3010189
Cuiffo BG, Campagne A, Bell GW, et al. MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell. 2014;15(6):762-74. doi:10.1016/j.stem.2014.10.001
Baratta MG, Schinzel AC, Zwang Y, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015;112(1):232-7. doi:10.1073/pnas.1422165112
Martz CA, Ottina KA, Singleton KR, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014;7(357):ra121. doi:10.1126/scisignal.aaa1877
Wang H, Yu C, Gao X, et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015;27(2):193-210. doi:10.1016/j.ccell.2014.11.017
Jeong SM, Xiao C, Finley LWS, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013;23(4):450-63. doi:10.1016/j.ccr.2013.02.024